Opening book details…
Can I read Combined cost-utility analysis of the 21-gene assay to guide chemotherapy in HR+/HER2- breast cancer on EtoBox?
Combined cost-utility analysis of the 21-gene assay to guide chemotherapy in HR+/HER2- breast cancer by Vladislav Berdunov; Steve Millen; Sarah Reynia; Nina Fryer; Peter Hall; Timothy Perren is a Medicine article available to read on EtoBox.
What is Combined cost-utility analysis of the 21-gene assay to guide chemotherapy in HR+/HER2- breast cancer about?
given in 25 cases (18.5%) and was recorded on the pathology form in all cases. Thirty-nine patients (28.8%) received NET and this was recorded on the pathology form in 21 (53.8%) cases. Conclusions: NACT use is well recorded. The use of NET is omitted in a large number of cases. This is an area of quality improvement focus and we have led departmental teaching and added a neoadjuvant therapy sticker to the pathology form with re-audit planned.
Who reads Combined cost-utility analysis of the 21-gene assay to guide chemotherapy in HR+/HER2- breast cancer?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Vladislav Berdunov; Steve Millen; Sarah Reynia; Nina Fryer; Peter Hall; Timothy Perren
- Publisher
- Elsevier BV
- Published
- 2023
- Language
- EN
- Field
- Medicine (Health Sciences)